Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

HK Inno.N (195940 KS): Modest Show In 1Q26; All Eyes on Maiden US Approval; Strengthening Pipeline

HK Inno.N (195940 KS): Mixed 2Q Result; Pipeline Progress to Maintain Positive Momentum

HK Inno.N (195940 KS): 2024 Will See Robust Profit Growth On Growing Momentum of Key Drug

HK Inno. N (195940 KS): Promising US Trial Result for K-CAB Raises Hope; Starts 2025 on Strong Note

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hk-inno-n-corp" target="_blank" data-smartkarma-citation="entities:33522:1" rel="noopener">HK inno.N (195940 KS)</a> reported strong 4Q25 result, with all key parameters showing improvement on sequential as well as YoY basis, driven by strong sales of prescription drug business.</li>
<li>HK inno’s U.S. partner has submitted a New Drug Application (NDA) to the FDA for K-CAB. The company expects to launch K-CAB in the U.S. by January next year.</li>
<li>Going ahead, HK inno is expected to maintain growth momentum, mainly riding on the back of prescription drug business, especially K-CAB. Bottomline is expected to widely outperform revenue growth.</li>
</ul>



HK inno.N (195940 KS) reported strong 4Q25 result, with all key parameters showing improvement on sequential as well as YoY basis, driven by strong sales of prescription drug business.
HK inno’s U.S. partner has submitted a New Drug Application (NDA) to the FDA for K-CAB. The company expects to launch K-CAB in the U.S. by January next year.
Going ahead, HK inno is expected to maintain growth momentum, mainly riding on the back of prescription drug business, especially K-CAB. Bottomline is expected to widely outperform revenue growth.


HK Inno.N (195940 KS): Prescription Drugs Drive 4Q25 Result; Maiden US Approval on Card